Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

• J. Remon ^[1] ; D. Isla ^[2] ; P. Garrido ^[3] ; J. de Castro ^[4] ; M. Majem ^[13] ; N. Viñolas ^[14] ; A. Artal ^[5] ; E. Carcereny ^[15] ; M. R. García-Campelo ^[16] ; P. Lianes ^[6] ; M. Provencio ^[7] ; O. Juan ^[17] ; P. Diz ^[8] ; R. Blanco ^[9] ; R. Lopez-Castro ^[10] ; I. Maestu ^[11] ; C. Vadell ^[12] ; E. Felip ^[1]
  1. [1] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  2. [2] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  3. [3] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  4. [4] Instituto de Investigación Sanitaria del Hospital Universitario La Paz

     Instituto de Investigación Sanitaria del Hospital Universitario La Paz

     Madrid, España

     
  5. [5] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  6. [6] Hospital de Mataró

     Hospital de Mataró

     Barcelona, España

     
  7. [7] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  8. [8] Complejo Asistencial Universitario de León

     Complejo Asistencial Universitario de León

     León, España

     
  9. [9] Hospital de Terrassa

     Hospital de Terrassa

     Barcelona, España

     
  10. [10] Hospital Universitario de Valladolid

      Hospital Universitario de Valladolid

      Valladolid, España

      
  11. [11] Hospital Universitario Doctor Peset

      Hospital Universitario Doctor Peset

      Valencia, España

      
  12. [12] Hospital de Manacor

      Hospital de Manacor

      Manacor, España

      
  13. [13] Hospital Sant Pau, Barcelona
  14. [14] Hospital Clínic, Barcelona
  15. [15] Hospital Germans Trias i Pujol, Barcelona
  16. [16] Complexo Hospitalario Universitatio A Coruña
  17. [17] Hospital Universitari Politècnic La Fe, Valencia

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 12, 2017, págs. 1537-1542
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.

    Methods WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.

    Results From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.

    Conclusion Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.